Mark Rothera, Silence Therapeutics CEO
With first human data, long-struggling Silence Therapeutics leaps into next big cardiovascular race
Drug companies have spent the last 40-plus years searching for increasingly high-tech ways of lowering bad cholesterol in hopes of curbing heart disease, still the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.